Researchers report on the BRIGHT AML 1019 Phase III trial.
Researchers explore the predictive capability of EVI1 expression.
ONCOLOGY spoke to Andre Goy, MD, MS about advances on leukemia, lymphoma, and myeloma treatments.
ONCOLOGY discussed therapy options for adult acute lymphoblastic leukemia with Dr. Elias Jabbour, MD, Professor of Medicine in the Department of Leukemia at the MD Anderson Cancer Center in Houston, Texas.
Researchers looked at the effect of diagnostic wait time on survival outcomes for patients with diffuse large B-cell lymphoma.
A new study found that enrolling appropriate patients with multiple myeloma into hospice may have cost implications.
Researchers conducted a study to define risk factors for cardiovascular adverse events in patients with multiple myeloma who were taking proteasome inhibitors.
The CALGB 50904 trial tested the addition of bortezomib to ofatumumab and bendamustine in patients with previously untreated high-risk follicular lymphoma.
A Mayo Clinic study tested metformin, believed to have anti-lymphoma activity, among patients with newly diagnosed diffuse large B-cell lymphoma or follicular lymphoma.
Researchers looked at second-generation tyrosine kinase inhibitors at their current prices to test treatment value for patients with chronic myeloid leukemia.